Viking Therapeutics, Inc. (VKTX)
26.86
+1.50
(+5.91%)
USD |
NASDAQ |
Oct 29, 16:00
26.58
-0.28
(-1.06%)
After-Hours: 04:45
Viking Therapeutics Enterprise Value : 2.720B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 2.720B |
| October 28, 2026 | 2.529B |
| October 27, 2026 | 2.469B |
| October 26, 2026 | 2.382B |
| October 23, 2026 | 2.406B |
| October 22, 2026 | 2.589B |
| October 21, 2026 | 2.659B |
| October 20, 2026 | 2.701B |
| October 19, 2026 | 2.489B |
| October 16, 2026 | 2.505B |
| October 15, 2026 | 2.785B |
| October 14, 2026 | 2.543B |
| October 13, 2026 | 2.693B |
| October 12, 2026 | 2.909B |
| October 09, 2026 | 2.931B |
| October 08, 2026 | 2.831B |
| October 07, 2026 | 2.934B |
| October 06, 2026 | 2.914B |
| October 05, 2026 | 3.029B |
| October 02, 2026 | 3.113B |
| October 01, 2026 | 3.186B |
| September 30, 2026 | 3.452B |
| September 29, 2026 | 3.213B |
| September 28, 2026 | 3.355B |
| September 25, 2026 | 3.651B |
| Date | Value |
|---|---|
| September 24, 2026 | 3.789B |
| September 23, 2026 | 4.361B |
| September 22, 2026 | 4.268B |
| September 21, 2026 | 3.015B |
| September 18, 2026 | 2.884B |
| September 17, 2026 | 2.927B |
| September 16, 2026 | 2.946B |
| September 15, 2026 | 2.996B |
| September 14, 2026 | 3.180B |
| September 11, 2026 | 3.233B |
| September 10, 2026 | 3.250B |
| September 09, 2026 | 3.317B |
| September 08, 2026 | 3.431B |
| September 04, 2026 | 3.570B |
| September 03, 2026 | 3.466B |
| September 02, 2026 | 3.410B |
| September 01, 2026 | 3.430B |
| August 31, 2026 | 3.326B |
| August 28, 2026 | 3.254B |
| August 27, 2026 | 3.452B |
| August 26, 2026 | 3.513B |
| August 25, 2026 | 3.488B |
| August 24, 2026 | 3.379B |
| August 21, 2026 | 3.456B |
| August 20, 2026 | 3.511B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.338T |
| Regeneron Pharmaceuticals, Inc. | 79.36B |
| Ironwood Pharmaceuticals, Inc. | 915.91M |
| Compass Therapeutics, Inc. | -34.06M |
| Structure Therapeutics, Inc. | 226.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -183.19M |
| Total Expenses (Quarterly) | 183.19M |
| EPS Diluted (Quarterly) | -1.552 |
| Earnings Yield | -20.13% |
| Normalized Earnings Yield | -20.13 |